Odulimomab 产品活性：Odulimomab (anti-LFA1) 是一种抗 LFA-1 单克隆抗体。Odulimomab 抑制 T 淋巴细胞增殖，对缺血再灌注损伤有保护作用。Odulimomab 可用于移植排斥反应和免疫疾病的研究。 产品来源： https://www.medchemexpress.cn/odulimomab.html 研究领域：Cytoskeleton 作用靶点：Integrin In Vitro: Odulimomab inhibits proliferation of T lymphocyte, and cytotoxicity and antibody production of T and Natural Killer (NK) cells in vitro. In Vivo: Odulimomab (1.5 and 0.75 mg/kg; i.p., 1.5 mg/kg for the first treatment then followed by daily injection of 0.75 mg/kg until sacrifice) shows protective effects against ischemia and reperfusion injury, and also repairs in renal function after transplantation. 相关产品：Cilengitide | Cyclo(-RGDfK) | Cucurbitacin B | GLPG0187 | E7820 | MK-0429 | CWHM-12 | Pyrintegrin | Lifitegrast | ATN-161 trifluoroacetate salt | Bexotegrast | Arg-Gly-Asp-Ser | Fibronectin | αvβ1 integrin-IN-1 TFA | Tirofiban | A-205804 | iRGD peptide | GPRP acetate | Carotegrast methyl | Eptifibatide | Vedolizumab | RGD peptide (GRGDNP) (TFA) | RGD | Natalizumab | Tetrac | Leukadherin-1 | BIO5192 | Cyclo(RGDyK) trifluoroacetate 品牌介绍: MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；设有专业的实验中心和严格的质控、验证体系；提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；产品的生物活性多经各国客户实验验证；Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；与世界各大制药公司及知名科研机构建立了长期的合作。